CRISPR/Cas9 – Market Players Snapshot
Published on 23 Feb, 2016
We're entering a new era in molecular biology.
A new tool based on a bacterial CRISPR-associated protein-9 nuclease (Cas9) from Streptococcus pyogenes will enable the development of efficient and reliable ways to make precise targeted changes to the genome of living cells.
The discovery however, is mired in a bitter patent war that has marred the biggest biotechnology advance since the polymerase chain reaction.
On the 11th of January, 2016, the USPTO approved a request to review a key patent pertaining to the CRISPR–Cas9 technique. This patent interference is estimated to be worth millions for the warring research institutions/ inventors.
Despite the ongoing patent war, a lot of startups and industry heavyweights have jumped on to the CRISPR/Cas9 bandwagon, seeing its potential in creating cures for various diseases such as AIDS, Cancer, and many more.
Here's a snapshot of the market players involved.